Economy · Finance
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
CNBC · World
Published 3 Nov 2026, 8:35 pm·57 min ago·1 min read
Listen to this story
Read aloud by your device
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Read the full story at CNBC · World
cnbc.com